Skip to main content
Top
Published in: Rheumatology and Therapy 3/2020

Open Access 01-09-2020 | Psoriatic Arthritis | Original Research

Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey

Authors: William Tillett, Joseph F. Merola, Diamant Thaçi, Elizabeth Holdsworth, Nicola Booth, L. Steve Lobosco, Gary Milligan, Matthew M. Hufford, Julie A. Birt, Wolf-Henning Boehncke

Published in: Rheumatology and Therapy | Issue 3/2020

Login to get access

Abstract

Introduction

Psoriatic arthritis (PsA) is a chronic, systemic, inflammatory disease where disease burden and quality of life (QoL) are affected by both joint and skin manifestations.

Methods

Patient and physician reported data were collected about 3200 patients in a cross-sectional survey of patients from nine countries. Patient-reported outcomes (PROs) included perceptions of symptom importance, EuroQol questionnaire (EQ-5D), Psoriatic Arthritis Impact of Disease (PsAID12), and Work Productivity and Activity Impairment (WPAI) Index. Outcomes were compared in patients with ‘joint-only’ and ‘joint and skin’ disease symptoms.

Results

Of the 3200 patients, 2703 had complete information for ‘joint-only’ or ‘joint and skin’ involvement and were included in the analysis. Patients had a mean age of 49.2 years, 45.2% were female, and 64.5% had ‘joint and skin’ involvement. Patients with ‘joint and skin’ involvement had higher mean tender and swollen joint counts (5.2 and 4.8) than patients who were ‘joint-only’ (2.0 and 1.5). Significantly more patients with active ‘joint and skin’ symptoms experienced a flare (currently or within the last 12 months) compared with ‘joint-only’ patients (34.9 vs. 23.2%, p < 0.001). When asked to prioritize the burden of symptoms, 61.6% of patients prioritized joints, 38.4% prioritized skin. Anxiety/depression was experienced by 41.4% of patients, 62.4% of whom indicated that both joint and skin symptoms were the cause. Patients with ‘joint and skin’ involvement reported significantly worse QoL, work productivity and activity impairment than ‘joint-only’ patients (EQ-5D index 0.79 vs. 0.85, p < 0.001; EQ-5D VAS 71.98 vs. 77.68, p < 0.001; PsAID12 2.91 vs. 1.66, p < 0.001; WPAI overall work impairment 25.61 vs. 16.32, p < 0.001).

Conclusions

PsA patients who experience ‘joint and skin’ symptoms had significantly worse clinical outcomes, health-related QoL, and work productivity compared with patients with ‘joint-only’ symptoms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548–54.CrossRefPubMed Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548–54.CrossRefPubMed
2.
go back to reference Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095–6.PubMed Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095–6.PubMed
3.
go back to reference Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65–70.CrossRefPubMed Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65–70.CrossRefPubMed
4.
go back to reference Gladman DD, Farewell V, Buskila D, et al. Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol. 1990;17(1):62–4.PubMed Gladman DD, Farewell V, Buskila D, et al. Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol. 1990;17(1):62–4.PubMed
5.
go back to reference McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42(6):778–83.CrossRefPubMed McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42(6):778–83.CrossRefPubMed
6.
go back to reference Mease PJ, Etzel CJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019;5(1):e000867.CrossRefPubMedPubMedCentral Mease PJ, Etzel CJ, Huster WJ, et al. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019;5(1):e000867.CrossRefPubMedPubMedCentral
7.
go back to reference Merola JF, Shrom D, Eaton J, et al. Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey. Rheumatol Ther. 2019;6(1):33–45.CrossRefPubMedPubMedCentral Merola JF, Shrom D, Eaton J, et al. Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey. Rheumatol Ther. 2019;6(1):33–45.CrossRefPubMedPubMedCentral
8.
go back to reference Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012;51(3):571–6.CrossRefPubMed Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012;51(3):571–6.CrossRefPubMed
9.
go back to reference Salaffi F, Carotti M, Gasparini S, et al. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009;7:25.CrossRefPubMedPubMedCentral Salaffi F, Carotti M, Gasparini S, et al. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009;7:25.CrossRefPubMedPubMedCentral
10.
go back to reference Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002;82(2):108–13.CrossRefPubMed Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol. 2002;82(2):108–13.CrossRefPubMed
11.
go back to reference Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45(2):151–8.CrossRefPubMed Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45(2):151–8.CrossRefPubMed
12.
go back to reference de Vlam K, Merola JF, Birt JA, et al. Skin involvement in psoriatic arthritis worsens Dooverall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational. Cross-Sect Study Rheumatol Ther. 2018;5(2):423–36.CrossRef de Vlam K, Merola JF, Birt JA, et al. Skin involvement in psoriatic arthritis worsens Dooverall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational. Cross-Sect Study Rheumatol Ther. 2018;5(2):423–36.CrossRef
13.
go back to reference Mease PJ, Karki C, Palmer JB, et al. Clinical and patient-reported outcomes in patients with Psoriatic Arthritis (PsA) by body surface area affected by psoriasis: results from the corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017;44(8):1151–8.CrossRefPubMed Mease PJ, Karki C, Palmer JB, et al. Clinical and patient-reported outcomes in patients with Psoriatic Arthritis (PsA) by body surface area affected by psoriasis: results from the corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017;44(8):1151–8.CrossRefPubMed
14.
go back to reference Kamalaraj N, El-Haddad C, Hay P, Pile K. Systematic review of depression and anxiety in psoriatic arthritis. Int J Rheum Dis. 2019;22(6):967–73.CrossRefPubMed Kamalaraj N, El-Haddad C, Hay P, Pile K. Systematic review of depression and anxiety in psoriatic arthritis. Int J Rheum Dis. 2019;22(6):967–73.CrossRefPubMed
15.
go back to reference Moverley AR, Vinall-Collier KA, Helliwell PS. It's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. Rheumatology (Oxford). 2015;54(8):1448–533.CrossRefPubMed Moverley AR, Vinall-Collier KA, Helliwell PS. It's not just the joints, it's the whole thing: qualitative analysis of patients' experience of flare in psoriatic arthritis. Rheumatology (Oxford). 2015;54(8):1448–533.CrossRefPubMed
16.
go back to reference Moverley AR, Waxman R, de Wit M, et al. Development of a flare instrument for use in psoriatic disease: a report from the 2015 GRAPPA annual meeting. J Rheumatol. 2016;43(5):974–8.CrossRefPubMed Moverley AR, Waxman R, de Wit M, et al. Development of a flare instrument for use in psoriatic disease: a report from the 2015 GRAPPA annual meeting. J Rheumatol. 2016;43(5):974–8.CrossRefPubMed
17.
go back to reference Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes—a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.CrossRefPubMed Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes—a means to understand. Curr Med Res Opin. 2008;24(11):3063–72.CrossRefPubMed
18.
19.
go back to reference EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef
20.
go back to reference Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.CrossRefPubMed Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.CrossRefPubMed
22.
go back to reference Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–45.CrossRefPubMed Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–45.CrossRefPubMed
23.
go back to reference Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789–93.PubMed Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9(5):789–93.PubMed
24.
go back to reference Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012–9.CrossRefPubMed Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012–9.CrossRefPubMed
26.
go back to reference Boehncke WH, Horvath R, Dalkilic E, et al. Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study. J Eur Acad Dermatolo Venereol. 2020. https://doi.org/10.1111/jdv.16251.CrossRef Boehncke WH, Horvath R, Dalkilic E, et al. Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study. J Eur Acad Dermatolo Venereol. 2020. https://​doi.​org/​10.​1111/​jdv.​16251.CrossRef
27.
go back to reference Husni ME, Fernandez A, Hauber B, et al. Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. Arthritis Res Ther. 2018;20(1):102.CrossRefPubMedPubMedCentral Husni ME, Fernandez A, Hauber B, et al. Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. Arthritis Res Ther. 2018;20(1):102.CrossRefPubMedPubMedCentral
28.
go back to reference Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215–9.CrossRefPubMed Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215–9.CrossRefPubMed
29.
go back to reference Kavanaugh A, McInnes IB, Krueger GG, et al. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013;65(10):1666–733.CrossRefPubMed Kavanaugh A, McInnes IB, Krueger GG, et al. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2013;65(10):1666–733.CrossRefPubMed
Metadata
Title
Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey
Authors
William Tillett
Joseph F. Merola
Diamant Thaçi
Elizabeth Holdsworth
Nicola Booth
L. Steve Lobosco
Gary Milligan
Matthew M. Hufford
Julie A. Birt
Wolf-Henning Boehncke
Publication date
01-09-2020
Publisher
Springer Healthcare
Published in
Rheumatology and Therapy / Issue 3/2020
Print ISSN: 2198-6576
Electronic ISSN: 2198-6584
DOI
https://doi.org/10.1007/s40744-020-00221-8

Other articles of this Issue 3/2020

Rheumatology and Therapy 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.